Baulieu J L, Guilloteau D, Delisle M J, Perdrisot R, Gardet P, Delépine N, Baulieu F, Dupont J L, Talbot J N, Coutris G
Service de Médecine Nucléaire et Ultra-Sons, Hôpital Bretonneau, Tours, France.
Cancer. 1987 Nov 1;60(9):2189-94. doi: 10.1002/1097-0142(19871101)60:9<2189::aid-cncr2820600913>3.0.co;2-c.
Fifty meta-iodobenzylguanidine (MIBG) scintiscans were performed in three groups of medullary thyroid cancer (MTC) patients. Group 1 (n = 11) included treated patients with normal calcitonin levels; Group 2 (n = 24) included patients with elevated calcitonin levels due to sporadic and isolated MTC; Group 3 (n = 15) included patients with elevated calcitonin levels due to familial MTC or multiple endocrine neoplasia Type IIA syndrome (MEN). In Group 1 three pheochromocytoma were depicted by MIBG scintiscan. In Group 2 MTC was seen in a small number of patients (3 of 24). In Group 3, besides adrenal hyperplasia and pheochromocytoma four patients, MIBG scintigraphy showed where MTC had localized and spread in almost half of patients (7 of 15). MIBG uptake occurred in patients with relatively high calcitonin level (greater than 0.6 nmol/l). These data indicate that in patients with familial MTC or MEN syndrome, MIBG scintiscan can be useful not only in detecting associated pheochromocytoma, but also in showing MTC.
